Liver Transplantation for Hepatocellular Carcinoma

  • Shusen Zheng


Starzl performed the world’s first liver transplantation (LT) for hepatocellular carcinoma (HCC) in the United States in 1963. In the world’s first 7 LTs, 3 of them were performed for HCC patients. By now, the history course of LT for HCC has gone through half a century. During these years, it has experienced the initial attempt, depression and today’s steady development.


Liver Transplantation Percutaneous Ethanol Injection Donor Liver Transplantation Milan Criterion Deceased Donor Liver Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. [1]
    Ringe B, Pichlmayr R, Wittekind C, et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg, 1991, 15: 270–285.PubMedCrossRefGoogle Scholar
  2. [2]
    Van Thiel D H, Carr B, Iwatsuki S, et al. The 11-year Pittsburgh experience with liver transplantation for hepatocellular carcinoma: 1981–1991. J Surg Oncol Suppl, 1993, 3: 78–82.PubMedCrossRefGoogle Scholar
  3. [3]
    Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med, 1996, 334: 693–699.PubMedCrossRefGoogle Scholar
  4. [4]
    Marsh J W, Dvorchik I, Bonham C A, et al. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer, 2000, 88: 538–543.PubMedCrossRefGoogle Scholar
  5. [5]
    Chen J, Xu X, Ling Q, et al. Role of Pittsburgh modified TNM criteria in prognosis prediction of liver transplantation for hepatocellular carcinoma. Chin Med J (Engl), 2007, 120: 2200–2203.Google Scholar
  6. [6]
    Yao F Y, Ferrell L, Bass N M, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology, 2001, 33: 1394–1403.PubMedCrossRefGoogle Scholar
  7. [7]
    Duffy J P, Vardanian A, Benjamin E, et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded: a 22-year experience with 467 patients at UCLA. Ann Surg, 2007, 246: 502–509, 509–511.PubMedCrossRefGoogle Scholar
  8. [8]
    Moray G, Karakayali F, Yilmaz U, et al. Expanded criteria for hepatocellular carcinoma and liver transplantation. Transplant Proc, 2007, 39: 1171–1174.PubMedCrossRefGoogle Scholar
  9. [9]
    Jonas S, Mittler J, Pascher A, et al. Living donor liver transplantation of the right lobe for hepatocellular carcinoma in cirrhosis in a European center. Liver Transpl, 2007, 13: 896–903.PubMedCrossRefGoogle Scholar
  10. [10]
    Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis, 2007, 25: 310–312.PubMedCrossRefGoogle Scholar
  11. [11]
    Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl, 2007, 13: 1637–1644.PubMedCrossRefGoogle Scholar
  12. [12]
    Lee S G, Hwang S, Moon D B, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl, 2008, 14: 935–945.PubMedCrossRefGoogle Scholar
  13. [13]
    Pawlik T M, Delman K A, Vauthey J N, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl, 2005, 11: 1086–1092.PubMedCrossRefGoogle Scholar
  14. [14]
    Mak K S, Tan K C. Liver transplantation for hepatocellular carcinoma: an Asian perspective. Asian J Surg, 2002, 25: 271–276.PubMedCrossRefGoogle Scholar
  15. [15]
    Xu X, Zheng S S, Liang T B, et al. Orthotopic liver transplantation for patients with hepatocellular carcinoma complicated by portal vein tumor thrombi. Hepatobiliary Pancreat Dis Int, 2004, 3: 341–344.PubMedGoogle Scholar
  16. [16]
    Zheng S S, Xu X, Wu J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation, 2008, 85: 1726–1732.PubMedCrossRefGoogle Scholar
  17. [17]
    Fan S T. Selection of HCC patients for liver transplantation: the Milan criteria, Hangzhou criteria and beyond. Hepatobiliary Pancreat Dis Int, 2008, 7: 233–234.PubMedGoogle Scholar
  18. [18]
    Busuttil R W. Liver transplantation for hepatocellular carcinoma: the Hangzhou experience. Hepatobiliary Pancreat Dis Int, 2008, 7: 235–236.PubMedGoogle Scholar
  19. [19]
    Sato Y, Yamamoto S, Oya H, et al. Preoperative human-telomerase reverse transcriptase mRNA in peripheral blood and tumor recurrence in living-related liver transplantation for hepatocellular carcinoma. Hepatogastroenterology, 2005, 52: 1325–1328.PubMedGoogle Scholar
  20. [20]
    Marsh J W, Finkelstein S D, Demetris A J, et al. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival. Liver Transpl, 2003, 9: 664–671.PubMedCrossRefGoogle Scholar
  21. [21]
    Majno P, Giostra E, Morel P, et al. Management of hepatocellular carcinoma in the waiting list before liver transplantation. J Hepatol, 2005, 42: S134–S143.PubMedCrossRefGoogle Scholar
  22. [22]
    Lencioni R, Crocetti L, Della Pina M C, et al. Guidelines for imaging focal lesions in liver cirrhosis. Expert Rev Gastroenterol Hepatol, 2008, 2: 697–703.PubMedCrossRefGoogle Scholar
  23. [23]
    Kamel I R, Liapi E, Fishman E K. Multidetector CT of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol, 2005, 19: 63–89.PubMedCrossRefGoogle Scholar
  24. [24]
    Willatt J M, Hussain H K, Adusumilli S, et al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology, 2008, 247: 311–330.PubMedCrossRefGoogle Scholar
  25. [25]
    Seale M K, Catalano O A, Saini S, et al. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics, 2009, 29: 1725–1748.PubMedCrossRefGoogle Scholar
  26. [26]
    Katyal S, Oliver J H, Peterson M S, et al. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000, 216: 698–703.PubMedGoogle Scholar
  27. [27]
    Harvey C J, Albrecht T. Ultrasound of focal liver lesions. Eur Radiol, 2001, 11: 1578–1593.PubMedCrossRefGoogle Scholar
  28. [28]
    Sugiyama M, Sakahara H, Torizuka T, et al. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol, 2004, 39: 961–968.PubMedCrossRefGoogle Scholar
  29. [29]
    Lee J W, Paeng J C, Kang K W, et al. Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med, 2009, 50: 682–687.PubMedCrossRefGoogle Scholar
  30. [30]
    Yuen M F, Lai C L. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol, 2005, 19: 91–99.PubMedCrossRefGoogle Scholar
  31. [31]
    Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology, 2002, 62 Suppl 1: 57–63.PubMedCrossRefGoogle Scholar
  32. [32]
    Toyoda H, Kumada T, Kiriyama S, et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol, 2006, 4: 111–117.PubMedCrossRefGoogle Scholar
  33. [33]
    Lao O B, Weissman J, Perkins J D. Pre-transplant therapy for hepatocellular carcinoma is associated with a lower recurrence after liver transplantation. Clin Transplant, 2009, 23: 874–881.PubMedCrossRefGoogle Scholar
  34. [34]
    Yao F Y, Bass N M, Nikolai B, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl, 2002, 8: 873–883.PubMedCrossRefGoogle Scholar
  35. [35]
    Ng K K, Lo C M, Liu C L, et al. Survival analysis of patients with transplantable recurrent hepatocellular carcinoma: implications for salvage liver transplant. Arch Surg, 2008, 143: 68–74.PubMedCrossRefGoogle Scholar
  36. [36]
    Belghiti J. Resection and liver transplantation for HCC. J Gastroenterol, 2009, 44 Suppl 19: 132–135.PubMedCrossRefGoogle Scholar
  37. [37]
    Llovet J M, Mas X, Aponte J J, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut, 2002, 50: 123–128.PubMedCrossRefGoogle Scholar
  38. [38]
    Cha C, Fong Y, Jarnagin W R, et al. Predictors and patterns of recurrence after resection of hepatocellular carcinoma. J Am Coll Surg, 2003, 197: 753–758.PubMedCrossRefGoogle Scholar
  39. [39]
    Liapi E, Geschwind J F. Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol, 2007, 25: 978–986.PubMedCrossRefGoogle Scholar
  40. [40]
    Shiina S. Japanese experience in ablation therapies for hepatocellular carcinoma. Hepatol Res, 2007, 37 (Suppl 2): S223–S229.PubMedCrossRefGoogle Scholar
  41. [41]
    Zhou W P, Lai E C, Li A J, et al. Prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg, 2009, 249: 195–202.PubMedCrossRefGoogle Scholar
  42. [42]
    Graziadei I W, Sandmueller H, Waldenberger P, et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl, 2003, 9: 557–563.PubMedCrossRefGoogle Scholar
  43. [43]
    Lo C M, Fan S T, Liu C L, et al. The role and limitation of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl, 2004, 10: 440–447.PubMedCrossRefGoogle Scholar
  44. [44]
    Vakili K, Pomposelli J J, Cheah Y L, et al. Living donor liver transplantation for hepatocellular carcinoma: increased recurrence but improved survival. Liver Transpl, 2009, 15: 1861–1866.PubMedCrossRefGoogle Scholar
  45. [45]
    Fouzas I, Sotiropoulos G C, Lang H, et al. Living donor liver transplantation for hepatocellular carcinoma in patients exceeding the UCSF Criteria. Transplant Proc, 2008, 40: 3185–3188.PubMedCrossRefGoogle Scholar
  46. [46]
    Fujiki M, Takada Y, Ogura Y, et al. Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver.transplantation for hepatocellular carcinoma. Am J Transplant, 2009, 9: 2362–2371.PubMedCrossRefGoogle Scholar
  47. [47]
    Di Sandro S, Slim A O, Giacomoni A, et al. Living donor liver transplantation for hepatocellular carcinoma: long-term results compared with deceased donor liver transplantation. Transplant Proc, 2009, 41: 1283–1285.PubMedCrossRefGoogle Scholar
  48. [48]
    Lo C M, Fan S T, Liu C L, et al. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg, 2007, 94: 78–86.PubMedCrossRefGoogle Scholar
  49. [49]
    Fisher R A, Kulik L M, Freise C E, et al., and the A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant, 2007, 7: 1601–1608.PubMedCrossRefGoogle Scholar
  50. [50]
    Takada Y, Ueda M, Ito T, et al. Living donor liver transplantation as a secondline secondline therapeutic strategy for patients with hepatocellular carcinoma. Liver Transpl, 2006, 12: 912–919.PubMedCrossRefGoogle Scholar
  51. [51]
    Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology, 2004, 127(5 Suppl 1): 277–282.CrossRefGoogle Scholar
  52. [52]
    Marcos A, Fisher R A, Ham J M, et al. Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation, 2000, 69: 1375–1379.PubMedCrossRefGoogle Scholar
  53. [53]
    Drixler T A, Vogten M J, Ritchie E D, et al. Liver regeneration is an angiogenesis-associated phenomenon. Ann Surg, 2002, 236: 703–711.PubMedCrossRefGoogle Scholar
  54. [54]
    Raia S, Nery J R, Mies S. Liver transplantation from live donors. Lancet, 1989, 2: 497.PubMedCrossRefGoogle Scholar
  55. [55]
    Barr M L, Belghiti J, Villamil F G, et al. A report of the Vancouver Forum on the care of the live organ donor: lung, liver, pancreas, and intestine data and medical guidelines. Transplantation, 2006, 81: 1373–1385.PubMedCrossRefGoogle Scholar
  56. [56]
    Ringe B, Strong R W. The dilemma of living liver donor death: to report or not to report? Transplantation, 2008, 85: 790–793.PubMedCrossRefGoogle Scholar
  57. [57]
    Human Organ Transplant Ordinance. The State Council of P. R. China. Implemented from June 1st, 2007.Google Scholar

Copyright information

© Zhejiang University Press, Hangzhou and Springer-Verlag Berlin Heidelberg 2012

Authors and Affiliations

  • Shusen Zheng
    • 1
  1. 1.Division of Hepatobiliary&Pancreatic Surgery and Liver Transplantation Center, Department of Surgery, First Affiliated HospitalZhejiang University College of MedicineHangzhouChina

Personalised recommendations